Boxol® Syrup: Each 5 ml of syrup contains 15 mg Ambroxol Hydrochloride BP.
Boxol® paediatric drops: Each ml of drop contains 6 mg Ambroxol Hydrochloride BP.
Boxol® SR capsule: Each capsule contains sustained release pellets of Ambroxol Hydrochloride BP equivalent to Ambroxol Hydrochloride BP 75 mg.
Indications: Productive cough, acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
Dosage & administration: Average daily dose (preferably after meal):
Boxol® Syrup: 2-5 years old: 2.5 ml (1/2 teaspoonful), 2-3 times daily.
5-10 years old: 5 ml (1 teaspoonful), 2-3 times daily.
10 years old and adults: 10 ml (2 teaspoonful), 2-3 times daily.
Boxol® paediatric drops: 0-6 months old: 0.5 ml, 2 times daily.
6-12 months old: 1 ml, 2 times daily.
1-2 years old: 1.25 ml, 2 times daily.
Boxol® SR capsule: Adults and children over 12 years old: 1 capsule, once daily.
Contraindications: Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
Side effects: Gastrointestinal side effects like epigastric pain, stomach overfilling may occur occasionally. Rarely allergic responses such as eruption, urticarial or angioneurotic edema has been reported.
Use in pregnancy & lactation: Teratogenic and foetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the 1st trimester. Safety during lactation has not been established yet.
Precautions: Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
Drug interactions: Ambroxol should not be taken simultaneously with antitussives (e.g. Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
Storage: Store in a cool and dry place, protected from light.
Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti-inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
Productive cough, acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.
Average daily dose (preferably after meal): Boxol Syrup: 2-5 years old: 2.5 ml teaspoonful), 2-3 times daily 5-10 years ml (1 teaspoonful), 2-3 times daily 10 years old and adults: 10 ml (2 teaspoonful), 2-3 times daily Boxol paediatric drops: 0-6 months old: 0.5 ml, 2 times daily 6-12 months old: 1 ml, 2 times daily 1-2 years old: 1.25 ml, 2 times daily Boxol SR capsule: Adults and children over 12 years old: 1 capsule, once daily.
Ambroxol should not be taken simultaneously with antitussives (e.g. Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
Teratogenic and foetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the 1st trimester. Safety during lactation has not been established yet.
Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
Store in a cool and dry place, protected from light.